Cerevast Therapeutics raises $6.5 million for clot-busting headframe device

Cerevast Therapeutics, which is developing an unique ultrasonic headframe device that’s used to break up blood clots in the brain, has raised $6.5 million of a $15 million venture capital round. The Redmond company has yet to release the device, which is being targeted for those suffering from ischemic stroke.

But the technology — which uses ultrasound energy to disrupt blood clots in the brain — is currently under review in Europe. It has received 75 U.S. patents on the technology to date.

Formed in 2009, the company is led by former Hazleton Laboratories, Glaxo Smithkline and Icos Corp. employee Bradford Zakes.

UPDATE: Zakes said that the company previously raised about $3 million, and that the latest money included seven investors. The lead investor, described as a global medical device company, did not want its name disclosed at this time.

The company employs less than a dozen workers, and Zakes said they plan to hire in the area of clinical operations, engineering and manufacturing. The company’s device has finished phase three trials with the FDA.